Myology research highlights
RSS feedZolgensma in children with type I SMA weighing over 13.5 kg
New real-life results for Zolgensma in 99 children with type I SMA, including 21 aged over 2 years and 7 weighing over 13.5 kg, collected from the six UK centres authorised to administer the gene therapy product, show : good tolerance of the product and its efficacy on motor function in older children (up to … [Read more]
The cost of neonatal screening for SMA
Researchers have studied the cost-benefit ratio of newborn screening (NBS) for SMA, which has been in place in Belgium for the past five years, by comparing children who were treated and monitored over a 30-month period: the children could have received treatment either following screening or because they were symptomatic, although the costs (direct and … [Read more]
After re-examination, the CHMP’s opinion on Translarna’s marketing authorisation for DMD remains unfavourable
On 15 September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) decided against renewing the marketing authorisation for Translarna (ataluren) in Duchenne muscular dystrophy (DMD). Developed by the laboratory PTC Therapeutics, the drug has until now benefited from a conditional marketing authorisation granted by the EMA for … [Read more]
Despite neonatal screening, neurodevelopmental disorders are reported in some SMA patients
The experts in charge of setting up newborn screening for spinal muscular atrophy (SMA) in Germany have warned of a number of cases of developmental disorders in children despite very early treatment with innovative therapies : 47 children from 49 families were screened between January 2018 and December 2020 for spinal muscular atrophy (SMA) and … [Read more]
Quantitative muscle imaging could be useful in assessing the impact of nusinersen in SMA
Dutch researchers have tested magnetic resonance imaging (MRI) of muscles as a possible tool for measuring the effectiveness of treatment of SMA with nusinersen (Spinraza) : eight treated children aged 9 years on average took part in the study, four with type 2 SMA and four with type 3 SMA, three complementary MRI techniques were … [Read more]
The clinical spectrum of MELAS and associated diseases
The Mayo Clinic team reviewed the records of 81 patients with characteristic clinical MELAS or with a positive genetic test for MELAS but without all the clinical criteria, with a mean follow-up of 5.8 years: 42 had MELAS, including 13 with a “late” onset, i.e. where the first neurological vascular pseudo-episode occurred after the age … [Read more]
Proper use of paracetamol prescriptions in SMA
Following problems of drug intolerance in patients with SMA who had received paracetamol for pain relief, Danish researchers undertook a pharmacokinetic study: six children and six adults with SMA were included and compared with eleven healthy subjects, all were given paracetamol at the usual recommended doses, repeated serum determinations of several paracetamol metabolites and hepatic … [Read more]
Histopathology of THOC2 splice-site arthrogryposis shows filamentous cytoplasmic inclusions
Following the description in 2021 of a family with X-linked arthrogryposis due to a mutation in the THOC2 gene, a French team reports : another family with the same mutation responsible for arthrogryposis. Muscle biopsy showed a wide variation in the size of muscle fibres, as well as the presence of cytoplasmic bodies in almost … [Read more]
An ultra-early case of mitofusin 2 deficiency
French researchers report the exceptional case of a foetus suffering from a deficiency in mitofusin 2, a mitochondrial protein encoded by the MFN2 gene already implicated in autosomal, dominant or recessive forms of Charcot-Marie-Tooth (CMT) disease: the diagnosis of multiple cerebral malformations was made antenatally after the demonstration of lissencephaly, polymicrogyria and cerebellar atrophy, a … [Read more]
Two new families with a rare form of CMT disease reported in Brazil
Researchers in Sao Paulo, Brazil, report the clinical and paraclinical observations of two families diagnosed with X-linked Charcot-Marie-Tooth (CMT) disease: mutations in the PKD3 gene, including a new one, were identified in these two families, enabling them to be classified as CMTX6, an ultra-rare subtype of CMT in which only a few patients have been … [Read more]
